Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Clinical Videos

A Guidewire-Free Approach for Percutaneous Closure of Left Ventricular Pseudoaneurysm

Tahir Bezgin, MD; Aziz Inan Celik, MD; Nart Zafer Baytugan, MD; Suleyman Karakoyun, MD; Metin Cagdas, MD

02/26/2024
Video 1. Left ventricle pseudoaneurysm seen on apical 2-chamber view.
Video 2. Left ventricle pseudoaneurysm seen on parasternal short-axis view.
Video 3. Leak into the pseudoaneurysm on transthoracic color Doppler echocardiography.
Video 4. Left ventriculography revealed the pseudoaneurysm.
Video 5. The ablation catheter was guided to the neck of the pseudoaneurysm, and the sheath was advanced safely through this catheter.
Video 6. An atrial septal defect occluder was deployed into the pseudoaneurysm.
Video 7. Transthoracic echocardiography confirmed the atrial septal defect occluder was in the proper position after the procedure (apical 2-chamber view).
Video 8. Transthoracic echocardiography confirmed the atrial septal defect occluder was in the proper position after the procedure (short-axis view).

 

Video Supplement to "A Guidewire-Free Approach for Percutaneous Closure of Left Ventricular Pseudoaneurysm" (Clinical Image).

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Journal of Invasive Cardiology or HMP Global, their employees, and affiliates. 
 


Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

News

News
Reflow Medical Enrolls First Patients in Pilot Study of Coronary Sirolimus-Eluting Retrievable Scaffold System (Spur Elute)
07/01/2024
Reflow Medical Press Release  San Clemente, CA – July 1, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of the Drug-Eluting...
Reflow Medical Press Release  San Clemente, CA – July 1, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of the Drug-Eluting...
Reflow Medical Press...
07/01/2024
Cath Lab Digest
Philips instantaneous wave-free ratio (iFR)
instantaneous wave-free ratio (iFR)
The Story of How Academics, Industry and Interventionalists Teamed Up to Reduce Cost, Time and Patient Discomfort in Treating Coronary Artery Disease
06/27/2024
Instantaneous wave-free ratio (iFR) is a pressure-derived index that does not require a pharmacological agent. iFR was invented by Dr. Justin Davies from Imperial College Healthcare NHS Trust in the UK, along with the team of clinicians at...
Instantaneous wave-free ratio (iFR) is a pressure-derived index that does not require a pharmacological agent. iFR was invented by Dr. Justin Davies from Imperial College Healthcare NHS Trust in the UK, along with the team of clinicians at...
Instantaneous wave-free ratio...
06/27/2024
Cath Lab Digest
Out-of-Hospital Care
Innovative Health and US Endovascular Announce Agreement to Drive Cost Savings in Ambulatory Surgery Centers and Office-Based Labs
06/27/2024
SCOTTSDALE, Ariz. – Innovative Health, Inc. and US Endovascular announced that they have entered into an agreement that will enable US Endovascular’s partners among ambulatory surgery centers (ASCs) and office-based labs (OBLs) to...
SCOTTSDALE, Ariz. – Innovative Health, Inc. and US Endovascular announced that they have entered into an agreement that will enable US Endovascular’s partners among ambulatory surgery centers (ASCs) and office-based labs (OBLs) to...
SCOTTSDALE, Ariz. – Innovative...
06/27/2024
Cath Lab Digest
TAVR
TAVR Treatment Remains Low in Bicuspid Aortic Valve Stenosis Patients, Finds GlobalData
06/25/2024
Despite receiving approval, international guidelines still recommend open surgical replacement in populations with bicuspid aortic valve (BAV) disease. As a result, TAVR treatment for BAVs still remains relatively low in comparison to...
Despite receiving approval, international guidelines still recommend open surgical replacement in populations with bicuspid aortic valve (BAV) disease. As a result, TAVR treatment for BAVs still remains relatively low in comparison to...
Despite receiving approval,...
06/25/2024
Cath Lab Digest
Aktiia bracelet and app
Remote monitoring
Study Finds Cuffless Blood Pressure Device Streamlines and Enhances Hypertension Management
06/25/2024
“The successful management of hypertension depends on patients being able to take blood pressure measurements easily and reliably outside of the traditional doctor’s office setting,” said corresponding author Naomi Fisher, MD.  “Cuffless...
“The successful management of hypertension depends on patients being able to take blood pressure measurements easily and reliably outside of the traditional doctor’s office setting,” said corresponding author Naomi Fisher, MD.  “Cuffless...
“The successful management of...
06/25/2024
Cath Lab Digest
SEmaglutide
Semaglutide Lowers Cardiovascular Risk Regardless of Blood Sugar
06/25/2024
A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to...
A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to...
A weekly dose of semaglutide 2.4...
06/25/2024
Cath Lab Digest
Pharmaceutical Therapy
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
06/25/2024
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with...
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with...
Alnylam Pharmaceuticals, Inc.,...
06/25/2024
Cath Lab Digest
Cordella (Endotronix, Inc.)
Remote monitoring
Endotronix Receives FDA Premarket Approval of the Cordella PA Sensor System for the Treatment of Heart Failure
06/24/2024
Cordella, which consists of the now PMA-approved Cordella PA Sensor and commercial Cordella™ HF System, enables comprehensive heart failure management in the home using pulmonary artery (PA) pressure, a leading indicator of congestion, and...
Cordella, which consists of the now PMA-approved Cordella PA Sensor and commercial Cordella™ HF System, enables comprehensive heart failure management in the home using pulmonary artery (PA) pressure, a leading indicator of congestion, and...
Cordella, which consists of the...
06/24/2024
Cath Lab Digest
OmnifyXR with GE HealthCare Allia IGS Platform
Imaging and AR
GE HealthCare and MediView Announce the World's First Installation and Clinical Use of Augmented Reality Interventional Suite
06/20/2024
This innovative augmented reality-based interventional radiology suite combines a holographic heads-up display streaming live medical imaging, 3D anatomy model visualization and advanced imaging technologies, while enabling the opportunity...
This innovative augmented reality-based interventional radiology suite combines a holographic heads-up display streaming live medical imaging, 3D anatomy model visualization and advanced imaging technologies, while enabling the opportunity...
This innovative augmented...
06/20/2024
Cath Lab Digest
Pharmaceutical Therapy
Novel Use of Existing Drug, N-acetyl cysteine (NAC), Could Significantly Cut Heart Attack Risk
06/19/2024

Georgia Institute of Technology News

Georgia Institute of Technology News ...
The researchers envision the drug will be most useful if a patient has already had a heart attack but is at risk of having a second one soon after. An IV injection of NAC could lower immediate risk. Eventually, NAC derivatives could be...
The researchers envision the drug will be most useful if a patient has already had a heart attack but is at risk of having a second one soon after. An IV injection of NAC could lower immediate risk. Eventually, NAC derivatives could be...
The researchers envision the...
06/19/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

News
Reflow Medical Enrolls First Patients in Pilot Study of Coronary Sirolimus-Eluting Retrievable Scaffold System (Spur Elute)
07/01/2024
Reflow Medical Press Release  San Clemente, CA – July 1, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of the Drug-Eluting...
Reflow Medical Press Release  San Clemente, CA – July 1, 2024 – Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of the Drug-Eluting...
Reflow Medical Press...
07/01/2024
Cath Lab Digest
Philips instantaneous wave-free ratio (iFR)
instantaneous wave-free ratio (iFR)
The Story of How Academics, Industry and Interventionalists Teamed Up to Reduce Cost, Time and Patient Discomfort in Treating Coronary Artery Disease
06/27/2024
Instantaneous wave-free ratio (iFR) is a pressure-derived index that does not require a pharmacological agent. iFR was invented by Dr. Justin Davies from Imperial College Healthcare NHS Trust in the UK, along with the team of clinicians at...
Instantaneous wave-free ratio (iFR) is a pressure-derived index that does not require a pharmacological agent. iFR was invented by Dr. Justin Davies from Imperial College Healthcare NHS Trust in the UK, along with the team of clinicians at...
Instantaneous wave-free ratio...
06/27/2024
Cath Lab Digest
Out-of-Hospital Care
Innovative Health and US Endovascular Announce Agreement to Drive Cost Savings in Ambulatory Surgery Centers and Office-Based Labs
06/27/2024
SCOTTSDALE, Ariz. – Innovative Health, Inc. and US Endovascular announced that they have entered into an agreement that will enable US Endovascular’s partners among ambulatory surgery centers (ASCs) and office-based labs (OBLs) to...
SCOTTSDALE, Ariz. – Innovative Health, Inc. and US Endovascular announced that they have entered into an agreement that will enable US Endovascular’s partners among ambulatory surgery centers (ASCs) and office-based labs (OBLs) to...
SCOTTSDALE, Ariz. – Innovative...
06/27/2024
Cath Lab Digest
Murugesan Figure 1
Clinical Videos
Vanishing Right Atrial Thrombus
06/26/2024
Video Supplement to "Vanishing Right Atrial Thrombus" (Clinical Image).
Video Supplement to "Vanishing Right Atrial Thrombus" (Clinical Image).
Video Supplement to "Vanishing...
06/26/2024
Journal of Invasive Cardiology
Clinical Images
Vanishing Right Atrial Thrombus
06/26/2024
An elderly woman presented with worsening shortness of breath for a duration of 3 days. She had a history of provoked deep vein thrombosis of the right lower limb with sub-massive pulmonary embolism, for which she was on oral anticoagulant...
An elderly woman presented with worsening shortness of breath for a duration of 3 days. She had a history of provoked deep vein thrombosis of the right lower limb with sub-massive pulmonary embolism, for which she was on oral anticoagulant...
An elderly woman presented with...
06/26/2024
Journal of Invasive Cardiology
TAVR
TAVR Treatment Remains Low in Bicuspid Aortic Valve Stenosis Patients, Finds GlobalData
06/25/2024
Despite receiving approval, international guidelines still recommend open surgical replacement in populations with bicuspid aortic valve (BAV) disease. As a result, TAVR treatment for BAVs still remains relatively low in comparison to...
Despite receiving approval, international guidelines still recommend open surgical replacement in populations with bicuspid aortic valve (BAV) disease. As a result, TAVR treatment for BAVs still remains relatively low in comparison to...
Despite receiving approval,...
06/25/2024
Cath Lab Digest
Aktiia bracelet and app
Remote monitoring
Study Finds Cuffless Blood Pressure Device Streamlines and Enhances Hypertension Management
06/25/2024
“The successful management of hypertension depends on patients being able to take blood pressure measurements easily and reliably outside of the traditional doctor’s office setting,” said corresponding author Naomi Fisher, MD.  “Cuffless...
“The successful management of hypertension depends on patients being able to take blood pressure measurements easily and reliably outside of the traditional doctor’s office setting,” said corresponding author Naomi Fisher, MD.  “Cuffless...
“The successful management of...
06/25/2024
Cath Lab Digest
SEmaglutide
Semaglutide Lowers Cardiovascular Risk Regardless of Blood Sugar
06/25/2024
A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to...
A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to...
A weekly dose of semaglutide 2.4...
06/25/2024
Cath Lab Digest
Pharmaceutical Therapy
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
06/25/2024
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with...
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with...
Alnylam Pharmaceuticals, Inc.,...
06/25/2024
Cath Lab Digest
Cordella (Endotronix, Inc.)
Remote monitoring
Endotronix Receives FDA Premarket Approval of the Cordella PA Sensor System for the Treatment of Heart Failure
06/24/2024
Cordella, which consists of the now PMA-approved Cordella PA Sensor and commercial Cordella™ HF System, enables comprehensive heart failure management in the home using pulmonary artery (PA) pressure, a leading indicator of congestion, and...
Cordella, which consists of the now PMA-approved Cordella PA Sensor and commercial Cordella™ HF System, enables comprehensive heart failure management in the home using pulmonary artery (PA) pressure, a leading indicator of congestion, and...
Cordella, which consists of the...
06/24/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement